USCOM LIMITED — Investor Presentation 2017

Dec 13, 2017

==> picture [70 x 84] intentionally omitted <==

“Never has scale been more important for the success and growth of a global business!”

DISCLAIMER

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the nor its officers or advisors or other warrants the Company any person accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom.

The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional as deem or for their own investment and all use enquiries they necessary appropriate purposes. Any of the information is at your own risk.

==> picture [94 x 540] intentionally omitted <==

ABOUT US

THE MEASURE OF LIFE

Uscom are the experts in circulation delivering innovative, practice changing non-invasive cardiovascular and pulmonary monitoring devices. Our devices are patent protected advancements on current devices, and provide improved measurements of the vital oxygen delivery system.

Our devices are changing the way cardiovascular and pulmonary medicine is practiced.

OVERVIEW

==> picture [215 x 156] intentionally omitted <==

==> picture [215 x 156] intentionally omitted <==

O U R V IS IO N

Uscom is an innovator in cardiovascular and pulmonary medical devices, developing new non-invasive technologies to address the challenges of global disease and health care.

O U R D R IV E

Uscom is driven by a commercial ambition to become a leader in the global healthcare business, and is poised for growth in 2018.

SUMMARY

RESULTS

Record revenue, sales, cash receipts (up 307% 5yrs, 72% 2yrs, and 32% 5yr CAGR)

• $3.5M revenue with intermittent monthly/quarterly cash flow positivity

2 international acquisitions

• High value IP across 3 sectors

High margin products

ACHIEVEMENTS

Leader in CV and pulmonary devices

New sales, marketing and distribution division to drive global sales

New regulatory approvals imminent

Volume manufacturing prepared Global operations

FUTURE

• 7 new products for China, Europe and USA

Expanded distribution - China

Uscom is a rapidly emerging global healthcare business poised for growth in 2018

• Revenue –$10, $20 and $50M short, mid and long term targets Re-valuation of assets ($20M -$200M)

Product pipeline – new IP

International partnerships

==> picture [421 x 540] intentionally omitted <==

USCOM TODAY

Reuters/Bloomberg	UCM.AX/UCM.AU
Market Cap	$18M
Current price	$0.15
2017 VWAP	$0.25
Shares on issue	114M
Free float	100%
Top 20 shareholders	65%
Major Shareholders	%
Prof Rob Phillips	19.96
Mr Gary Davey	5.48
Dr Stephen Woodford	8.96

OVERVIEW

==> picture [215 x 156] intentionally omitted <==

==> picture [215 x 156] intentionally omitted <==

P R O D U C T S

USCOM 1A – Ultrasonic Cardiac Output Monitor for sepsis, fluid, heart failure, hypertension, pre-eclampsia

BP+ - Blood pressure and heart failure for hypertension, pharma, heart failure SpiroSonic – Ultrasonic spirometers for asthma and COPD

GL O B A L S A L E S

Current Uscom results are based on USCOM 1A global sales Uscom has acquired 2 companies and their IP and rebranded and integrated these operations, devices and IP into Uscom. This creates a new global sales focus and Uscom is working to establish new global sales, marketing and distribution channels

GOVERNANCE

==> picture [162 x 191] intentionally omitted <==

Ms Sheena Jack Non-executive CEO of HCF

==> picture [165 x 192] intentionally omitted <==

Associate Prof Rob Phillips Executive Uscom Limited

==> picture [163 x 191] intentionally omitted <==

==> picture [165 x 189] intentionally omitted <==

Mr Christian Bernecker Mr Brett Crowley Non-executive Secretary Mr Chao Xian (David) He Non-executive

MEDICAL ADVISORY

==> picture [229 x 137] intentionally omitted <==

----- Start of picture text -----

Prof. Colin Sullivan Australia
Sleep Medicine
----- End of picture text -----

==> picture [960 x 446] intentionally omitted <==

----- Start of picture text -----

Prof. Colin Sullivan Australia
Sleep Medicine
Prof. C.P.Lau | Hong Kong
Cardiolology/Electrophysiology
Prof. Didier Payen | France
Critical Care Medicine
Prof. Peter Lichtenthal | USA
Cardiac Anaesthesia
Prof. Nigel Sharrock | USA
Anaesthesia
Prof. Stephane Carlier | Belgium
Invasive Cardiolology/Physiology
Prof. Malcolm West | Australia
Cardiolology/Hypertension
----- End of picture text -----

OUR RESULTS

==> picture [385 x 390] intentionally omitted <==

----- Start of picture text -----

2012 2013 2014 2015 2016 2017
$3,498,959.00
$2,936,504.00
$2,039,426.00
$1,377,716.00
$1,010,942.00
$864,099.00
----- End of picture text -----

T OTA L A NNU A L R E V E NU E

Strong revenue, sales and receipts growth 307% growth over the last 5 years 72% in the last 2 years CAGR of 30-40% PA for the last 5 years

Intermittent cash flow +ve in 2017

Growth is expected to accelerate with the revenue provided by the new BP+ and SpiroSonic devices as they reach market in 2018.

GROWTH MODELS

==> picture [462 x 388] intentionally omitted <==

----- Start of picture text -----

CAGR and 5 Year Projected Revenue
30
25
20
15
10
5
0
2017 2018 2019 2020 2021 2022
20% CAGR 32% CAGR 50% CAGR
$M AUD
----- End of picture text -----

These are simple mathematical models

and do not in any way represent forecasts

RELATIVE PERFORMANCE

==> picture [466 x 384] intentionally omitted <==

----- Start of picture text -----

ASX Indices 5 Year Compound PA Growth Rate (CAGR)
35
32
30
25
20 18
15 13
10 8
7
5 3
0.6
0
%
----- End of picture text -----

OUR ACQUISITIONS

INVESTED IN NEW TECHNOLOGY

==> picture [185 x 137] intentionally omitted <==

==> picture [137 x 137] intentionally omitted <==

==> picture [137 x 137] intentionally omitted <==

==> picture [137 x 137] intentionally omitted <==

Uscom has invested in technology with two corporate acquisitions: central blood pressure, and pulmonary function monitoring.

• We have integrated the companies, redesigned, optimised, and rebranded the new devices prepared the products for market.

2018 will see the launch of 7 new products to market, and new revenue.

The USCOM 1A is a non-invasive advanced hemodynamic monitor that measures cardiovascular function using Doppler ultrasound to detect abnormalities and guide treatment. The USCOM 1A has major applications in Paediatrics, Emergency, Intensive Care, Anaesthesia and Pre-eclampsia.

==> picture [270 x 197] intentionally omitted <==

==> picture [270 x 197] intentionally omitted <==

The BP+ measures blood pressure and pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac

catheterisation. The Uscom BP+ Reporter is a patient archiving, analysis and reporting software for use with the Uscom BP+. This system will revolutionise hypertensive management

SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi-path ultrasound technology. SpiroSonic devices can be coupled with mobile applications and proprietary software with wireless interfacing to provide remote telemonitoring of asthma, COPD and OLD.

==> picture [270 x 197] intentionally omitted <==

OUR BENEFITS

TOP 10 CAUSES OF DEATH GLOBALLY – 2015 (WHO)

M E E T ING GLOB A L C LINIC A L NE E D S

==> picture [794 x 310] intentionally omitted <==

----- Start of picture text -----

Ischaemic heart disease
C LINIC A L NE E D S
Stroke
Lower repiratory infection
Uscom devices address conditions responsible
COPD
for 75% of all deaths worldwide (WHO criteria).
Tracheal, bronchus, lung cancers Heart failure
Diabetes mellitus Sepsis
Alzheimer Hypertension
Diarrhoel diseases Asthma
COPD
Tuberculosis
Road injury
0 2 4 6 8 10
Death in millions
----- End of picture text -----

REGULATORY

==> picture [245 x 99] intentionally omitted <==

==> picture [247 x 248] intentionally omitted <==

Regulatory approval is required for device sales into China (CFDA), Europe (CE), FDA (USA) and Australia (TGA). Uscom has a number of pending approvals into various jurisdictions over the next 12 months which will allow sales into new markets.

BP+: SpiroSonic: CFDA – Submission; CFDA – Submission; CE – Pending; CE – Acquired; FDA - Submission FDA – Submission; TGA – Acquired TGA – Acquired

USCOM 1A:

CFDA – Acquired; CE – Acquired; FDA – Acquired; TGA - Acquired

OUR WORLD

==> picture [712 x 419] intentionally omitted <==

==> picture [289 x 524] intentionally omitted <==

MILESTONES FY17

Uscom made 23 price sensitive ASX announcements for the 2017 financial year.

OUR SCIENCE

Patents and publications prove the value of Uscom technology to investors and the community.

==> picture [249 x 248] intentionally omitted <==

30 Patents

Patents provide the legal protection for the value of our IP, and Uscom has strong property protection of all its product suites. To defend future revenue streams Uscom has more than 30 wide reaching and active patents across major international jurisdictions.

500 Publications

Uscom science and technology has also been recognised in more than 500 academic papers and presentations as a practice leader.

PRODUCT LAUNCH

==> picture [115 x 68] intentionally omitted <==

==> picture [78 x 47] intentionally omitted <==

IT ’S A B IG D E A L

• The BP+ is great science, and is:

• • On board the International Space Station

• • Used by UK servicemen and women to study hypertension on Mount Everest

• • In drug evaluation trials with big pharma

• • The emerging BP monitor of choice

• • Hypertension occurs in aprox 1:3 adults worldwide and costs aprox $372B USD globally PA

==> picture [180 x 163] intentionally omitted <==

LUNG FUNCTION

FOR EVERY BREATH YOU TAKE

Lung disease (asthma and COPD) occurs in

approximately 20% of the population and is increasing SpiroSonic devices improve the diagnosis and treatment of lung disease

Device redesign and rebranding complete New distribution in the US, China and SE Asia. Emerging eHealth applications for personalised home monitoring

Discussions with leading global distributors Preparing for global markets in 2018 Community cost 11.1B GBP, 20B Euro, 50B USD

==> picture [220 x 65] intentionally omitted <==

SPIROMETRY DEVICES

S OF T WA R E

DE V IC E S

==> picture [116 x 183] intentionally omitted <==

A P P L IC AT ION

GROWTH STRATEGY

==> picture [156 x 156] intentionally omitted <==

==> picture [157 x 157] intentionally omitted <==

==> picture [34 x 50] intentionally omitted <==

Distribution and manufacturing

Global CV and Pulmonary Devices

• Global regulatory

• World leading devices

• •

• New products in pipeline China+ market expansion

==> picture [33 x 50] intentionally omitted <==

==> picture [156 x 156] intentionally omitted <==

==> picture [157 x 156] intentionally omitted <==

==> picture [34 x 51] intentionally omitted <==

Saving Lives – Uscom products

• Saving Lives – Uscom products Growth in revenue and scale • • Adoption Grow revenue to $20M

• • • Clinical practice Grow cap value to $200M

• Grow cap value to $200M

==> picture [158 x 181] intentionally omitted <==

GROWTH CHINA

==> picture [527 x 464] intentionally omitted <==

----- Start of picture text -----

China USA
GROWTH GDP SPEND GDP GOAL
20
18
12 12
%
5.8
5.5
----- End of picture text -----

C H INA IS A M A JOR S T R AT E GIC M A R K E T

1.4B population in 31 provinces 20% PA China health growth UCM CEO on NSW Government China Advisory 10 year history + China Government partners CFDA BP+ and SpiroSonic initiated China revenue targets $20M

GROWTH SALES

==> picture [647 x 399] intentionally omitted <==

----- Start of picture text -----

Damien Linnett
Global Sales Manager
GROWTH IN DISTRIBUTION AGREEMENTS Appointed 2017
Bea Onal
25
Marketing Coordinator
Appointed 2017
16
12
11
Denise Pater
11 Global Distribution
50
Manager
43
41
36
6
23
12
Bev Jacobson
2013 2014 2015 2016 2017 2018 Clinical Relations
Manager
ROW China
----- End of picture text -----*

INVESTMENT

Uscom is a high growth, de-risked medical device and technology company. While this is a simple overview it demonstrates a commitment to continued growth and delivery on operational fundamentals.

High value, de-risked investment ✓ Experienced management ✓ Strong underlying business ✓ Established revenue growth history ✓ Premium products and markets ✓

Diversified, validated and lifesaving technologies ✓ Aggressive global growth strategy ✓ 7 new products for 3 new markets in the next 12mths ✓ Further product pipeline ✓ Strategic opportunities ✓

RISKS

In a complex world unpredictable events can intervene in plans and strategies, and this also applies to Uscom, with a list of potential risks for the business going forward. While potential risks exist, management are always watchful and plan to respond rapidly and effectively to diminish their impact on the company. Growth and adequate funding – scale up stress Component availability/manufacturing impacting product supply Global economy – Brexit, USA, N Korea, South China etc. Lumpy revenue – small, rapidly growing and unpredictable Regulatory – delays and cost Under performance of distributors Competitive risks and patent breaches Key personnel risks Unforeseen ….

WHY NOW

After 5 years growth and investment Uscom is preparing for new revenue as we deliver 7 new products to global markets to supplement our already strong growth

New products – 1 to 8 (+700%) New distribution – 53 to 75 (+32%) New regulatory approvals (CE, FDA and CFDA)

More revenue – $3.5M to $10M, 20M, 50M Incremental growth – strategic partnerships? Revaluation of assets ($20M -$200M)

FUTURE AMBITION

==> picture [407 x 439] intentionally omitted <==

----- Start of picture text -----

HEALTHCARE REVENUE 2016
30
27.05
18.29
17
16.67
15.77
$B USD
11 11.17
10.11
9.66
0.0024
----- End of picture text -----

Multiple premium products with pipeline Proven growth trends

Experienced management Multiple markets and jurisdictions China connections Patent protected IP De-risked bio-tech Small cap, under-valued

Immediate revenue increments Rapidly growing global sector Strategic opportunities

To build devices to meet current and impending volume sales orders Complete regulatory processes in multiple jurisdictions Increase technical, marketing and sales staff to support expanding international operations

Grow China market with new digital strategy, clinical support and materials CAPITAL GROWTH

31

==> picture [66 x 78] intentionally omitted <==

"Uscom has acquired global assets to ensure reliable revenue growth over the next decade. Our strategy is to efficiently deliver the devices we have developed into global markets, and grow shareholder value.”

==> picture [267 x 274] intentionally omitted <==

==> picture [428 x 274] intentionally omitted <==

==> picture [267 x 274] intentionally omitted <==

==> picture [262 x 261] intentionally omitted <==

NO COMPETITION 0 out of 10 of the market leaders can compete with the USCOM 1A The USCOM 1A’s superior Doppler technology is manufactured by Uscom, Australia.

Reliability and Replicability SV Beat to Beat Non-invasive Cost Effective Portable Simple

USCOM 1A - The Future of Hemodynamics

USCOM 1A COMPETITORS

System	Manufacturer	Technology	Rel+Rep	Non-invasive	Simple	Cost	Portable	SV beat to beat	Training
USCOM 1A	Uscom	Doppler	✓	✓	✓	✓	✓	✓	✓
CardioQ	Deltex	Doppler	✓	✗	✓	✗	✓	✗	✗
Echo	Many	Ultrasound	✓	✓	✗	✗	✓	✗	✗
ICON / Aesculon	Osypka	Bio Impedance	✗	✓	✓	✗	✓	✗	✓
NiCOM	Cheetah	Bio Reactance	✗	✓	✓	✗	✓	✗	✓
Clearsight (Nexfin)	Edwards	PPW / BP / Plethysmo	✗	✓	✓	✓	✓	✗	✓
LiDCO	LiDCO	LiCl dilution + PPW	✓	✗	✗	✗	✗	✗	✗
LiDCOrapid	LiDCO	PPW / BP	✗	✗	✓	✗	✗	✗	✗
PiCCO	Pulsion	PPW / BP Modified Tx	✓	✗	✗	✗	✗	✗	✗
FloTrac	Edwards	PPW	✗	✗	✗	✗	✗	✗	✗
PAC	Many	Thermodilution	✗	✗	✗	✗	✗	✗	✗

==> picture [267 x 274] intentionally omitted <==

==> picture [428 x 274] intentionally omitted <==

==> picture [267 x 274] intentionally omitted <==

==> picture [267 x 267] intentionally omitted <==

NO COMPETITION

Australian Made USD 2,950

45 Seconds Monitor ± Reporter

Central blood pressure is the new gold standard measure for the detection and management of cardiovascular diseases. The BP+ and BP+ Reporter is the ideal cardiovascular research combination for the home, clinic or research laboratory.

CE, FDA, TGA, CFDA * Aortic Waveform Physical Form

BP+ - Revolutionizing Hypertension

BP+ COMPETITORS

Uscom BP+	TensioMed	BPLab	IEM	Alam Medical	SunTech	AtCor	WelchAllyn
Australia	Hungary	Russia	Germany	France	USA	Australia	USA
USD 2,950	USD 6,000	USD 7,000	USD 7,000		USD 3,200	USD 14,000	USD 3,200
45 seconds	2 min	2 min	2 min	A few sec +		1 min
				prep
Stand-alone± BP+ Reporter	Needs computer	ABP, needs computer	ABP, needs computer	Needs computer	ABP, needs computer for cBP	Needs computer	ABP, needs computer for cBP
CE, FDA, TGA, CFDA *	CE	CE	CE, FDA	CE	CE, FDA	CE, FDA, TGA	CE, cBP not available in USA
Aortic waveform	Central systolic BP	Rough waveform	Rough waveform		Rough waveform	Rough waveform
Physical model	Statistical regression	Transfer function	Transfer function		Transfer function	Transfer function

Australian made

USD 1,890 Dual path ultrasound Accurate/auto calibration Digital/Bluetooth/rechargeable FreeFlo sensor/Reporter/SpO2

Hygeinic

==> picture [430 x 275] intentionally omitted <==

==> picture [267 x 540] intentionally omitted <==

NO COMPETITION The SpiroSonic Ultrasonic spirometer uses high fidelity multi-path ultrasound for pulmonary function testing.

• SpiroSonic For Every Breath You Take

SPIROSONIC COMPETITORS

Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube	Uscom SpiroSonic Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990 Dual Path Ultrasound Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path Ultrasound Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable Multiple iterations Multiple iterations Multiple iterations Multiple iterations Multiple iterations Consumable turbines Multiple iterations Accurate Consumable tube
	Uscom SpiroSonic	Welch Allyn	Schiller	Sibelmed	Vitalograph	MIR	Carefusion	NDD
	Australia	USA	Switzerland	Spain	USA	Italy	USA	Switzerland
	SpiroSonic	SpiroPerfect	Spirovit SP-1	Dataspir Touch	Pneumotrac	Spirodoc	Microloop	EasyOne PLus
	USD 1,890	USD 2,100	USD 1,850	USD 2,300	USD 2,030	USD 1,580	USD 2,180	USD 1,990
	Dual Path Ultrasound	Diff Pressure	Diff Pressure	Turbine	Diff Pressure	Turbine	Turbine	Single Path Ultrasound
	Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations Consumable turbines	Multiple iterations	Accurate Consumable tube

==> picture [291 x 219] intentionally omitted <==

==> picture [245 x 69] intentionally omitted <==

==> picture [215 x 102] intentionally omitted <==

LOOKING FORWARD FY18 is planned to be another year of growth.

==> picture [268 x 281] intentionally omitted <==

USCOM MEDIA

“Medical device company Uscom says it has revolutionised the way hypertension and heart failure are monitored, with the release of new technology to assess blood pressure.”

The Australian, 30[th] October 2017

==> picture [165 x 540] intentionally omitted <==

==> picture [270 x 281] intentionally omitted <==

USCOM NEWS

Great opportunity to join The Premier of NSW, The Hon Gladys Berejiklian, the NSW Minister for Health and Medical Research, The Hon Brad Hazzard, and the Governor of Guangdong Mr Ma Xingrui as a Health and Medical Devices delegate at the NSW Delegation to the 26th NSW-Guangzhou Joint Economic Meeting on the 5th December in Guangzhou, China.

==> picture [243 x 281] intentionally omitted <==

“Companies like…Uscom are selling product world-wide and earning highly significant export income and all are on the verge of moving from losses to sustainable profits.”

BioTech Daily Sep 2017

Medical device maker USCOM has China in focus as it nears profitability.

Financial Review, Jan 2017

FOUNDER-RUN

“Research suggests that founder-run businesses outperformed the broader market. This seems intuitive, with firms like Amazon, Facebook, and Google being among the strongest performers in the world in recent years. Closer to home, Seek, Harvey Norman, Flight Centre, and Nick Scali have all been successful founder-run businesses. We think there are some important lessons here.” Livewire Markets’ Weekend Edition, 18 November 2017

==> picture [175 x 72] intentionally omitted <==

SMALL CAPS

“The case for small caps to structurally outperform is stronger than ever. Reasons for this include: - The high level of inside ownership & alignment with investors

- The leverage smalls have to M&A

- Smalls are typically less researched than large caps which give investors an ‘information bias’ if they do the work

• Leveraging technology”

David Allingham, Eley Griffiths, Livewire Markets’ Weekend Edition, 18 November 2017

==> picture [175 x 72] intentionally omitted <==

==> picture [71 x 85] intentionally omitted <==

"Uscom has acquired global assets to ensure reliable revenue growth over the next decade. Our strategy is to efficiently deliver the devices we have developed into global markets, and grow shareholder value.”